Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.33 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046611 | 0.92 | ALDH1A1 (0.45) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| SCHEMBL11700915 | 0.85 | PSMB5 (0.46) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| SCHEMBL11793557 | 0.83 | PSMB5 (0.49) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| SCHEMBL10452977 | 0.83 | PSMB5 (0.49) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| Methane SCHEMBL39470 | 0.81 | PSMB5 (0.47) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| Ethane SCHEMBL6550192 | 0.81 | PSMB5 (0.47) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| SCHEMBL1924715 | 0.81 | AMY1A (0.42) | ESR2UGT2B17TAS1R3TAS1R1TAS1R2 | |
| Methane SCHEMBL4437465 | 0.80 | PSMB5 (0.46) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| SCHEMBL15517754 | 0.80 | UGT2B17 (0.39) | UGT2B17KDM4EALDH1A1LMNAGAA | |
| SCHEMBL3685646 | 0.80 | UGT2B17 (0.39) | UGT2B17KDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11060027-B2 | Macromolecular antioxidants based on dual type moiety per molecule: structures, methods of making and using the same | POLNOX CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200392406-A1 | MACROMOLECULAR ANTIOXIDANTS BASED ON DUAL TYPE MOIETY PER MOLECULE: STRUCTURES, METHODS OF MAKING AND USING THE SAME | POLNOX CORPORATION | 2020-12-17 | — | — | US | disclosed |
| WO-2018160879-A2 | MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME | POLNOX CORPORATION (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-3071544-A2 | MACROMOLECULAR ANTIOXIDANTS BASED ON DUAL TYPE MOIETY PER MOLECULE: STRUCTURES METHODS OF MAKING AND USING THE SAME | Polnox Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077635-A2 | MACROMOLECULAR ANTIOXIDANTS BASED ON DUAL TYPE MOIETY PER MOLECULE: STRUCTURES METHODS OF MAKING AND USING THE SAME | POLNOX CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-1456173-A1 | TRANSITION-METAL-CATALYZED PROCESS FOR THE CONVERSION OF ALKENES TO STERICALLY HINDERED SUBSTITUTED N-ALKOXYAMINES | Ciba SC Holding AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053931-A1 | TRANSITION-METAL-CATALYZED PROCESS FOR THE CONVERSION OF ALKENES TO STERICALLY HINDERED SUBSTITUTED N-ALKOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11060027-B2 | Macromolecular antioxidants based on dual type moiety per molecule: structures, methods of making and using the same | LPO, GPX4, DUOX2 | ESR2 1741/4885UGT2B17 1124/4885KDM4E 3627/4885 |
| US-20200392406-A1 | MACROMOLECULAR ANTIOXIDANTS BASED ON DUAL TYPE MOIETY PER MOLECULE: STRUCTURES, METHODS OF MAKING AND USING THE SAME | LPO, GPX4, DUOX2 | ESR2 1741/4885UGT2B17 1124/4885KDM4E 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.